Kansas Board of Pharmacy considers new access for addiction counselors to KTRACS database

The Joint Committee on Administrative Rules and Regulations convened on June 10, 2025, to discuss significant changes regarding access to the KTRACS database, which tracks controlled substances in Kansas. A key focus of the meeting was a proposed regulation that would expand the list of individuals authorized to access this sensitive database to include licensed addiction counselors.

During the discussions, committee members raised concerns about patient confidentiality and the implications of allowing addiction counselors access to personal medical records. One representative questioned the necessity of this access, noting that addiction counselors do not prescribe or administer medications. The response indicated that the board believes this access is essential for addiction counselors to effectively treat individuals struggling with substance use disorders.

The committee sought clarity on the origin of requests for this expanded access, with one member recalling an email from a former KTRACS director. However, specific details about the number of requests or the organizations behind them were not readily available. The board's representative acknowledged the need to consult further with the board to provide comprehensive answers.

Concerns were also raised about the regulatory framework governing who can access KTRACS records. It was noted that only addiction counselors authorized by a supervising prescriber would have access, but the specifics of these restrictions were not clearly defined in the proposed regulation. This lack of clarity led to discussions about potential legal implications, including issues related to unreasonable search and seizure.

In addition to the KTRACS access discussion, the committee addressed two other regulations concerning the revocation of emergency classifications for certain substances, Clonazolam and Fruvomazolam, which had been permanently scheduled by the Kansas Legislature in 2024. The board confirmed that revoking these regulations would have no economic impact.

The meeting concluded with a call for further examination of the proposed changes to KTRACS access, emphasizing the need for careful consideration of patient privacy and the regulatory framework before implementation. The board committed to providing additional information to address the committee's concerns in future communications.